NFKB1 and neoplasm: The exact molecular characterization of the key oncogenic mechanisms of constitutive NF-κB activation either shared by several or unique to certain lymphoid malignancies might allow the rational design of therapeutic strategies tailored to the specific tumor entities and might thus significantly improve lymphoma therapy.